Niagen Bioscience doubles share buyback program to $20 million

Niagen Bioscience Inc. (NASDAQ: NAGE) announced its board of directors authorized an increase in the company's share repurchase program from $10 million to $20 million of outstanding common stock.

The company has repurchased approximately $2.6 million of its common stock through March 17, 2026, under the program. The share repurchase program is authorized through October 31, 2027, unless modified, suspended, or terminated by the board.

"The recent repurchase of our common stock and $10 million increase in our program reflect the conviction we have in our strategy and long-term value," said Rob Fried, CEO of Niagen Bioscience. "We will continue to take advantage of the disconnect between NAGE's market valuation and the underlying strength of our business opportunistically."

Repurchases may be executed through open market transactions, privately negotiated transactions, or pursuant to trading plans in accordance with securities laws. The program does not obligate the company to repurchase any specific amount of stock.

Niagen Bioscience focuses on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research. The company's products include Tru Niagen consumer supplements and Niagen Plus pharmaceutical-grade intravenous and injectable products.

You May Also Be Interested In

• Verastem reports early trial data for KRAS G12D cancer drug VS-7375
• uniQure prices $225 million public offering at $45.50 per share
• CVG to join Russell 2000 and Russell 3000 indexes June 26